ACRS — ACLARIS THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ACLARIS THERAPEUTICS INC (ACRS)
ACLARIS THERAPEUTICS INC (ACRS) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $11M. Across recent filings, tracked investors recorded 4 new positions, 2 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ACRS
How many top investors track ACRS
A small number of top investors own this.
ACRS Ownership Composition
How ACLARIS THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other98.1%
- Hedge Funds1.9%
Tracked investors reporting ACRS
- Ken GriffinMar 31, 2026Citadel AdvisorsShares2.8MValue$10.6M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares756.1KValue$2.8M% Portfolio0.00%
- Steve CohenDec 31, 2025Point72 Asset ManagementShares87.2KValue$262.4K% Portfolio0.00%
Recent activity
- $3.2MFeb 17, 2026
- $2.8MMay 15, 2026
- New$262.4KFeb 17, 2026
- Increased$10.6M(20.24%)May 15, 2026
- Increased$7.1M(63.59%)Feb 17, 2026
- New$2.7MNov 14, 2025
Frequently asked questions
- How many institutional investors hold ACRS?
- 3 tracked institutional investors disclosed a position in ACRS (ACLARIS THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ACRS?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ACRS, valued at $11M.
- Did institutional ownership of ACRS increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 2 increased, 0 reduced, and 0 fully exited ACRS.
- Where does this ACRS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.